216 related articles for article (PubMed ID: 15883972)
1. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
3. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site.
Yamamoto D; Takai S; Miyazaki M
Biochem Biophys Res Commun; 2007 Mar; 354(4):981-4. PubMed ID: 17275782
[TBL] [Abstract][Full Text] [Related]
4. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
[TBL] [Abstract][Full Text] [Related]
5. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
7. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
[TBL] [Abstract][Full Text] [Related]
8. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
[TBL] [Abstract][Full Text] [Related]
9. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
10. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence.
Guy JL; Jackson RM; Acharya KR; Sturrock ED; Hooper NM; Turner AJ
Biochemistry; 2003 Nov; 42(45):13185-92. PubMed ID: 14609329
[TBL] [Abstract][Full Text] [Related]
13. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
14. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
15. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs.
Fernandez JH; Neshich G; Camargo AC
Genet Mol Res; 2004 Dec; 3(4):554-63. PubMed ID: 15688321
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
17. Effect of varying chain length between P(1) and P(1') position of tripeptidomimics on activity of angiotensin-converting enzyme inhibitors.
Chaudhary S; Vats ID; Chopra M; Biswas P; Pasha S
Bioorg Med Chem Lett; 2009 Aug; 19(15):4364-6. PubMed ID: 19523823
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory antibodies to human angiotensin-converting enzyme: fine epitope mapping and mechanism of action.
Skirgello OE; Balyasnikova IV; Binevski PV; Sun ZL; Baskin II; Palyulin VA; Nesterovitch AB; Albrecht RF; Kost OA; Danilov SM
Biochemistry; 2006 Apr; 45(15):4831-47. PubMed ID: 16605251
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Natesh R; Schwager SL; Sturrock ED; Acharya KR
Nature; 2003 Jan; 421(6922):551-4. PubMed ID: 12540854
[TBL] [Abstract][Full Text] [Related]
20. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates.
Bersanetti PA; Andrade MC; Casarini DE; Juliano MA; Nchinda AT; Sturrock ED; Juliano L; Carmona AK
Biochemistry; 2004 Dec; 43(50):15729-36. PubMed ID: 15595828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
